KIF18A Targeting Therapies FDA EMA Approval Clinical Trials By Indication Company Country Drug Class Report
Highest Phase Of Development: Phase-I/II
KIF18A Targeting Therapies In Clinical Trials: > 10 Therapies
KIF18A Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase
KIF18A Targeting Therapies Market Development Trends Insight
KIF18A Therapies Technology Platforms Insight
Download Report: https://www.kuickresearch.com/report-kif18a-targeting-inhibitor-kif18a-inhibitor-clinical-trials-kif18a-targeting-therapy
The global KIF18A targeting therapies market is rapidly gathering momentum as KIF18A has emerged as a key vulnerability in cancers characterized by chromosomal instability. As a mitotic kinesin motor protein essential for chromosome alignment during cell division, KIF18A is overexpressed in malignancies such as ovarian and triple-negative breast cancers, making it a promising target for precision oncology with potentially lower toxicity than traditional chemotherapies.
Although no KIF18A-targeted therapy is commercially available yet, the field is progressing quickly. Clinical pipelines include more than 10 therapies, with several in early clinical development. Among the frontrunners is ATX‑295 from Accent Therapeutics, an oral, best-in-class small-molecule inhibitor that recently entered a Phase I/II dose-escalation study in patients with advanced solid tumors, including ovarian and triple-negative breast cancer. It's employed with biomarker-enriched enrollment based on genomic instability markers like whole-genome doubling, and has received FDA Fast Track status—accelerating its path forward.
The clinical landscape includes global contributions from leading biotechs such as Volastra Therapeutics, advancing multiple small-molecule inhibitors including Sovilnesib (AMG‑650) in Phase I for platinum-resistant ovarian cancer, and VLS‑1488 in Phase I/II across chromosomal instability-high tumors. Accent's ATX‑295 stands currently at the most advanced Phase I/II stage, with trials in the US and potentially Asia-Pacific, suggesting geographic development convergence.
Technological innovation underpins expansion in this field. Development is dominated by small-molecule inhibitors designed to halt KIF18A's motor activity at kinetochores, causing mitotic catastrophe in cancer cells. Alternative approaches include disrupting upstream regulatory pathways like phosphorylation, and leveraging AI-driven drug discovery platforms. For example, Insilico Medicine's Chemistry42 and PandaOmics platforms generated a macrocyclic KIF18A inhibitor (ISM9682), showcasing the power of AI to enhance specificity and efficiency in drug design.
Market trends demonstrate strong growth potential. The first commercial KIF18A-targeting therapy is expected by 2030, propelled by fast track designations and positive preclinical data. The rich pipeline, combined with precision biomarker strategies, supports a robust developmental roadmap, aligning with unmet clinical needs in CIN-high solid tumors and potentially extending to hematologic malignancies where KIF18A overexpression correlates with poor prognosis.
Regional development trends show clinical leadership based in the US and Europe, where companies like Accent and Volastra are active, while China and other Asia-Pacific markets are engaging through global trial participation and local biotech collaborations. Multi-region trial footprints and biomarker-defined patient enrollment strategies are shaping global development dynamics.
Our Global KIF18A Targeting Therapies Market Report offers detailed insights into this evolving therapeutic area. It profiles more than ten clinical-stage candidates by company, indication, country, and development phase, with a deep focus on ATX‑295 as the leading Phase I/II program. The report evaluates technology platforms, including small-molecule motor inhibitors and AI-enabled discovery, and analyzes biomarker-led patient selection models. Regional development trends and regulatory environments are mapped, and strategic partnerships and investments are examined.
For pharmaceutical executives, biotech investors, and drug development leaders, this report provides a strategic foundation. It outlines market drivers, technological innovations, and clinical milestones that are poised to transform KIF18A from a promising target into an approved therapeutic by 2030, potentially offering new treatment options for patients with chromosomally unstable tumors.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
3 hours ago
- Newsweek
FDA Issues Risk Warning After Mushrooms Recalled Nationwide
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. Food and Drug Administration (FDA) has issued a national advisory and classified a recent mushroom recall as Class I, the agency's highest level risk designation, due to potential Listeria monocytogenes contamination. Newsweek contacted Hofood99 Inc via telephone for comment outside of usual working hours on Sunday and left a voicemail message. Why It Matters The Class I recall status indicates that the product poses a risk of causing serious health consequences or death if consumed. Listeria monocytogenes can lead to severe and sometimes fatal infections, especially during pregnancy, and for newborns, elderly adults, and people with weakened immune systems. Although no illnesses have been reported, the risk to public health is significant, prompting the warnings from the FDA. This incident highlights ongoing concerns surrounding food safety, especially in the distribution and handling of perishable produce. What to Know As reported by Newsweek, the firm-initiated recall affects enoki mushrooms distributed by Hofood99 Inc, located at 21903 56th Avenue Oakland Gardens, New York, 11364. The affected mushrooms were sold in 200‑gram green plastic bags and marked with UPC 6 976532 310051 on the back label; a picture of enoki mushrooms is outlined in green on the front of the package. The recall number is H-0261-2025. Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) The 90 boxes of affected product were shipped to retailers nationwide and tested positive for Listeria during routine sampling conducted by the Michigan Department of Agriculture. Consumers are advised not to eat the product and to either discard it or return it to the store where it was purchased for a full refund. Symptoms of Listeria infection may include high fever, muscle aches, nausea, diarrhoea, and in severe cases, complications such as meningitis or miscarriage. Consumers are advised to clean and sanitise refrigerators and any surfaces that may have come into contact with the recalled mushrooms, as the bacteria can survive and spread in cold environments. What People Are Saying The FDA in the original alert in part: "The contamination was discovered after samples were collected from a store in Michigan and subsequent analysis by Michigan Department of Agriculture & Rural Development (MDARD) Laboratory Division revealed the presence of Listeria monocytogenes." The FDA, as stated on its website: "A recall is a method of removing or correcting products that are in violation of laws administered by the Food and Drug Administration (FDA). Recall is a voluntary action that takes place because manufacturers and distributors carry out their responsibility to protect the public health and well-being from products that present a risk of injury or gross deception or are otherwise defective. What Happens Next Consumers with questions can contact Hofood99 Inc. at (917) 756‑9833 during business hours of 9:00 a.m. to 2:00 p.m., Monday to Friday. Further updates are available on the FDA's website. Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts.
Yahoo
6 hours ago
- Yahoo
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
Atai Life Sciences N.V. (NASDAQ:ATAI) is among the . Aegis Capital analysts have reaffirmed their Buy rating on Atai Life Sciences N.V. (NASDAQ:ATAI), with an unchanged price target of $8.00, following the favorable Phase 2b results of the BPL-003 treatment for the company's Treatment Resistant Depression (TRD). Around 193 depression patients, who didn't respond to previous treatment, were part of the Phase 2b trial testing three doses: 0.3 mg, 8 mg, and 12 mg. Not only the 8mg but also the 12mg dose showcased statistically significant improvement in an FDA-accepted measurement of depression, with a healthy side-effect profile. A close-up of a medical professional providing advice to a patient struggling with opioid use disorder. The research firm believes these robust results strengthen the company's efforts to proceed to a Phase 3 clinical program, which would result in marketing approval. Going forward, Atai Life Sciences N.V. (NASDAQ:ATAI) plans to schedule a post-Phase 2 meeting with the FDA, with the Phase 3 trial expected to begin only at the end of the upcoming year. Another noteworthy development is the company's recent $50 million private capital raise, which involved the sale of 18,264,840 common shares with 25% warrant coverage at the market price. Moves like these highlight Atai Life Sciences N.V. (NASDAQ:ATAI)'s capacity to raise cash when needed. Atai Life Sciences N.V. (NASDAQ:ATAI) is a German clinical-stage biopharmaceutical company that researches, develops, and markets mental health treatments in the United States, Germany, and Canada. With a market capitalization of $587.639 million, the company is committed to healing mental health disorders. While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Business Upturn
11 hours ago
- Business Upturn
Today's Opportunity Meets XRP's 5-Year Outlook — PFMCrypto Launches Short-Term XRP Mining Plan
New York, NY, July 12, 2025 (GLOBE NEWSWIRE) — The price trajectory of Ripple (XRP) has always been hard to predict. In December 2020, the SEC lawsuit cast a long shadow over the token. Although the legal pressure eased by mid-2024—and Ripple Labs even launched an XRP-backed stablecoin—the market's response was unexpectedly bearish. However, by 2025, XRP made a dramatic recovery. In early July, XRP's 5-year ROI finally aligned with that of Bitcoin (BTC), reigniting interest among long-term holders. In response to this renewed momentum, PFMCrypto has launched a new 5-day XRP cloud mining contract, giving users a reliable way to earn XRP daily while they await future price milestones. First-time users receive a $10 signup bonus, making it easy to begin earning immediately—without any upfront investment. Explore the new 5-day XRP mining contract now at: Five-Day Contract, Instant Daily Rewards. Traditional mining is often cost-prohibitive and technically complex. But PFMCrypto's cloud-based mining system changes the game—offering 100% remote access, AI-optimized performance, and daily payouts. The newly released 5-day mining contract is perfect for both cautious investors and experienced holders. By applying the $10 signup bonus, users can instantly activate a plan and receive $0.66 in daily XRP rewards—all without spending their own money. This approach makes it easier than ever to stay active in the XRP ecosystem while the long-term outlook continues to unfold. Key Features of PFMCrypto's XRP Cloud Mining Contracts: – No Hardware Required: Mine from anywhere with just a browser or APP —no gear or tech skills needed – Daily Payouts: Receive predictable daily rewards based on the contract you choose – Secure Asset Management: Enterprise-grade custody ensures your crypto stays safe – Multiple Contract Durations: Tailored to your goals—short-term or long-term Mining Options for Every Kind of XRP Investor： Whether you're a first-time user or a seasoned holder, PFMCrypto has designed a wide range of XRP mining contracts for all experience levels: $10 Contract – 1 Day – Earn $0.66 daily (free with signup bonus) $100 Contract – 2 Days – Earn $3.00 daily + $2 extra reward $500 Contract – 5 Days – Earn $6.15 daily $5,000 Contract – 30 Days – Earn $78.50 daily $20,000 Contract – 45 Days – Earn $380.00 daily For those who believe in XRP's five-year growth but want daily progress, these plans offer a smart, low-risk way to stay involved and grow holdings passively. Click here to explore more contracts, all of which support XRP mining. What Makes PFMCrypto's XRP Mining Contracts Different? – 100% Remote Mining Mining contracts can be activated instantly, without the need for physical equipment or technical setup. PFMCrypto's fully remote system ensures seamless access and a hassle-free experience from any location worldwide. – Principal Guarantee All invested capital is fully protected. Upon completion of each contract term, the initial investment is returned in full, offering confidence and financial security. – AI-Powered Optimization A proprietary AI-driven engine optimizes mining operations in real time, maintaining consistent earnings even during periods of low market activity and volatility. – Stable Daily Returns Contracts are structured to deliver reliable daily income, helping to minimize exposure to long-term market fluctuations and support the generation of steady passive returns. How to Begin Earning with PFMCrypto? Register an Account – Instantly receive a $10 bonus and daily login rewards. Click here to register and join the PFMCrypto mining community. Choose a Contract – Start with the 5-day plan or explore other tiers. Start Mining – Sit back while the system mines XRP and pays you every 24 hours. A Smarter Way to Mine as XRP Matures. Since its founding in 2018, PFMCrypto has helped users around the world generate passive crypto income through remote, secure, and AI-powered cloud mining. With support for XRP, BTC, SOL, DOGE, and more, the platform is built for both beginners and pros looking to grow their assets without complicated setups or large capital requirements. 'As XRP reclaims its position in the top tier of crypto assets, holders are asking what's next,' said a PFMCrypto spokesperson. 'Our 5-day mining contracts provide a low-risk, high-access way to benefit from XRP's long-term future—while earning from it today.' The next five years may be uncertain—but your next five days don't have to be. Start mining XRP now at Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks. There is a possibility of financial loss. You are advised to perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
